Shire’s VEYVONDI received EU market authorization for the treatment of bleeding events and the prevention or treatment of surgical bleeding in adults with von Willebrand disease (VWD), the most common inherited bleeding disorder. It affects up to one percent of the global population. The product, which has been approved in the US more than two years ago under the trade name VONVENDI®, is the first and only recombinant treatment for adults living with VWD.
It relates to a substance that was patented by the Max Delbrück Center for Molecular Medicine Berlin-Buch (MDC) and licensed to industry by Ascenion, the MDC’s technology transfer partner.
For further information:
See Shire's press release